Taking a Measured Approach to Toxicity Data in Phase I Oncology Clinical Trials.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 26467385.
- Also identified by DOI 10.1158/1078-0432.CCR-15-2005 and PMC identifier 4738103.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The standard categorical system for assessing attribution of toxicity to study drug(s) in phase I trials is cumbersome and uninformative. Although a binary system ("related" vs. "unrelated") would be sufficient to define maximum tolerated dose (MTD), a probability estimation would better support dose selection for randomized dose-ranging phase II trials.
Medical subject headings
- Dose-Response Relationship, Drug
- Maximum Tolerated Dose